ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,849.72
-1.76%
US Tech 100
19,966.80
-1.77%
다우존스 지수
43,191.24
-1.48%
Bitcoin
83,704.70
-2.78%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Syndax Pharmaceuticals Inc (SNDX) 시세

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc (SNDX)

NASDAQ
15.48
-0.16
(-1.02%)
마감 04 3월 6:00AM
15분 지연
14.9243
-0.5557
(-3.59%)
시간외 거래: 9:55AM
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
14.9243
매수가
14.84
매도가
15.88
거래량
3,100,951
14.84 일간 변동폭 16.50
12.06 52주 범위 25.16
market_cap
1.274B
전일 종가
15.64
개장가
16.41
최근 거래 시간
3
@
15.87
마지막 거래 시간
재정 규모
US$ 48,052,374
VWAP
15.496
평균 볼륨(3m)
2,479,650
발행 주식
85,357,675
배당수익률
-
주가수익률
-6.31
주당순이익(EPS)
-2.45
매출
-
순이익
-209.36M

Syndax Pharmaceuticals Inc 정보

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and ... Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.syndax.com
본부
Wilmington, Delaware, USA
설립됨
-
Syndax Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker SNDX. The last closing price for Syndax Pharmaceuticals was US$15.64. Over the last year, Syndax Pharmaceuticals shares have traded in a share price range of US$ 12.06 to US$ 25.16.

Syndax Pharmaceuticals currently has 85,357,675 shares in issue. The market capitalisation of Syndax Pharmaceuticals is US$1.33 billion. Syndax Pharmaceuticals has a price to earnings ratio (PE ratio) of -6.31.

Syndax Pharmaceuticals (SNDX) 옵션 플로우 요약

전체 옵션 플로우 보기

전체 흐름

강세

순 프리미엄

166k

Calls / Puts

100.00%

매수 / 매도

33.33%

OTM / ITM

300.00%

Sweeps 비율

0.00%

SNDX 최신 뉴스

추가 뉴스

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Edgar (US Regulatory)
19 시간 전
SNDX (-1.02%)

Form 8-K - Current report
Edgar (US Regulatory)
19 시간 전
SNDX (-1.02%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
13 2월 2025
SNDX (-1.02%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
11 2월 2025
SNDX (-1.02%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
11 2월 2025
SNDX (-1.02%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
11 2월 2025
SNDX (-1.02%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-1.3857-8.496014714916.3116.3114.9243198528215.51566651CS
41.09437.9125090383213.8316.9513.64239449115.28636358CS
12-1.7707-10.606169511816.69516.9512.06247965014.19062481CS
26-5.6257-27.375669099820.5522.512.06187422515.70621461CS
52-9.0557-37.763552960823.9825.1612.06145047417.82678109CS
156-1.3957-8.5520833333316.3229.8611.215113445018.8075477CS
2605.214353.70030895989.7129.866.8892212118.69978114CS

SNDX - Frequently Asked Questions (FAQ)

What is the current Syndax Pharmaceuticals share price?
The current share price of Syndax Pharmaceuticals is US$ 14.9243
How many Syndax Pharmaceuticals shares are in issue?
Syndax Pharmaceuticals has 85,357,675 shares in issue
What is the market cap of Syndax Pharmaceuticals?
The market capitalisation of Syndax Pharmaceuticals is USD 1.33B
What is the 1 year trading range for Syndax Pharmaceuticals share price?
Syndax Pharmaceuticals has traded in the range of US$ 12.06 to US$ 25.16 during the past year
What is the PE ratio of Syndax Pharmaceuticals?
The price to earnings ratio of Syndax Pharmaceuticals is -6.31
What is the reporting currency for Syndax Pharmaceuticals?
Syndax Pharmaceuticals reports financial results in USD
What is the latest annual profit for Syndax Pharmaceuticals?
The latest annual profit of Syndax Pharmaceuticals is USD -209.36M
What is the registered address of Syndax Pharmaceuticals?
The registered address for Syndax Pharmaceuticals is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Syndax Pharmaceuticals website address?
The website address for Syndax Pharmaceuticals is www.syndax.com
Which industry sector does Syndax Pharmaceuticals operate in?
Syndax Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ACONAclarion Inc
US$ 7.511
(124.21%)
90.51M
BTOGBit Origin Ltd
US$ 0.3209
(76.32%)
292.77M
BTAIBioXcel Therapeutics Inc
US$ 3.73
(72.69%)
146.91M
CLROClearOne Inc
US$ 0.78
(50.87%)
33.44M
ATLNAtlantic International Corporation
US$ 3.1674
(50.11%)
615.57k
BLNEEastside Distilling Inc
US$ 0.7237
(-90.57%)
53.57k
NVNINVNI Group Ltd
US$ 0.3798
(-62.40%)
38.31M
AGMHAGM Group Holdings Inc
US$ 0.1304
(-60.32%)
9.47M
PLRXPliant Therapeutics Inc
US$ 1.38
(-59.88%)
19.51M
AGHAureus Greenway Holdings Inc
US$ 2.23
(-59.01%)
3.8M
NVDANVIDIA Corporation
US$ 114.06
(-8.69%)
409.42M
BTOGBit Origin Ltd
US$ 0.3209
(76.32%)
291.2M
FTFTFuture FinTech Group Inc
US$ 0.249
(23.27%)
218.59M
SPGCSacks Parente Golf Inc
US$ 0.187
(-10.35%)
160.53M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 12.6667
(-5.82%)
153.57M

SNDX Discussion

게시물 보기
dinogreeves dinogreeves 6 월 전
Have you looked at TIL on Friday.
👍️0
Monksdream Monksdream 6 월 전
SNDX a buy again
👍️0
dinogreeves dinogreeves 1 년 전
SNDX had the highest volume today for some reason, this is either going to tank hard on Monday or hit 30...50....60 dollars. Took my chances with 600 shares.
👍️0
dinogreeves dinogreeves 1 년 전
Possibly a huge run on Monday, very possible or they missed the trial. Huge 400 million in the coffers and monster institutional ownership.
👍️0
dealerschool2006 dealerschool2006 4 년 전
Nice rebound today for $SNDX, beat the street and conference call was successful!!!
👍️0
dealerschool2006 dealerschool2006 4 년 전
SNDX recovering from panic sale!!!
👍️0
dealerschool2006 dealerschool2006 4 년 전
Panic sale for SNDX on positive results...May options wide swings...
👍️0
DaytraderJohn DaytraderJohn 5 년 전
Its interesting how a company such as this can go on to have revenue loss of 50m+ per year. Yet still give higher ups 200k+ cash bonuses and large salaries.

They have no product revenue.

I expect shares to be diluted after earnings.

Read their 10k. I guess it's a gamble play incase one day they do get approval.
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX looks like this run is going to continue. Let’s hit $15.00 this week folks
👍️0
ClayTrader ClayTrader 5 년 전
* * $SNDX Video Chart 01-31-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX next week is going to be fun
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX Hope you guys went all in here...Have a great weekend see y’all on Monday
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX holding this baby!
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX keep climbing baby! Going be going up all next week
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX looking awesome from my call at $8.00
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX got us a runner folks!!!
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX Chomp Chomp Chomp!
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX Weeeeeeeeeee
👍️0
BoilerRoom BoilerRoom 5 년 전
Going to run folks.
👍️0
BoilerRoom BoilerRoom 5 년 전
$SNDX in at $8.00
👍️0
TheFinalCD TheFinalCD 5 년 전
News News Alert: Syndax Announces $35.0 Million Offering of Common Stock...
👍️0
whytestocks whytestocks 6 년 전
News: $SNDX Syndax Announces $26.2 Million Offering of Common Stock and Warrants

WALTHAM, Mass. , March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnolo...

Find out more https://marketwirenews.com/news-releases/syndax-announces-26-2-million-offering-of-common-stock-and-warrants-7897910.html
👍️0
DewDiligence DewDiligence 6 년 전
SNDX 3Q18 results—cash=$89.6M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-clinical-and-business-update-300744153.html
👍️0
Spartak Spartak 6 년 전
Well, the company is done. What a disaster.
👍️0
DewDiligence DewDiligence 6 년 전
SNDX -21%/AH on PFS failure in HR+/HER2- breast cancer:

https://finance.yahoo.com/news/syndax-host-conference-call-phase-200500374.html

The trial continues to test for statsig OS every six months until Nov 2019.
👍️0
DewDiligence DewDiligence 6 년 전
SNDX -20% on no news—sell-off could be related to recent general bearishness for PD-(L1) add-on agents, which was a theme at ESMO.
👍️0
DewDiligence DewDiligence 6 년 전
SNDX upgrades BoD:

https://www.prnewswire.com/news-releases/syndax-announces-changes-to-its-board-of-directors-300718661.html
👍️0
DewDiligence DewDiligence 6 년 전
#msg-143766395
👍️0
DewDiligence DewDiligence 6 년 전
SNDX phase-3 PFS data now expected in 4Q18 (rather than 3Q18); I essentially called this back in May (#msg-140923103, bottom):

https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-in-non-small-cell-lung-cancer-300717717.html
👍️0
DewDiligence DewDiligence 6 년 전
#msg-143642544
👍️0
DewDiligence DewDiligence 6 년 전
SNDX 2Q18 CC transcript:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-152734163.html
👍️0
DewDiligence DewDiligence 7 년 전
SNDX 2Q18 items—6/30/18 cash=$98.4M…

PR:
http://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-second-quarter-2018-financial

CC slides:
http://ir.syndax.com/static-files/18eaf63a-6c93-45cd-8272-60479300c153
👍️0
Spartak Spartak 7 년 전
When does pounding stop? Someone hummers it pretty badly.
👍️0
fsantes fsantes 7 년 전
Ill keep a look out for some then!... I’ve been looking as well. Thank you!
👍️0
DewDiligence DewDiligence 7 년 전
No. I generally post anything that's material.
👍️0
fsantes fsantes 7 년 전
Have you heard any new news on SNDX?
👍️0
fsantes fsantes 7 년 전
I really appreciate it. Bought some shares as one advisor mentioned it to me but keeping track of what’s going on on it
👍️0
DewDiligence DewDiligence 7 년 전
SNDX requested that the SEC keep this document in redacted form:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-ex101_169.htm

This was filed as an exhibit to the most recent 10-Q.
👍️0
fsantes fsantes 7 년 전
Do you know what’s the news that came out about? When I look it’s blank..
👍️0
DewDiligence DewDiligence 7 년 전
SNDX, NKTR ink clinical-trial collaboration for Entinostat + NK-214 in second-lime melanoma:

https://www.prnewswire.com/news-releases/syndax-and-nektar-therapeutics-announce-immuno-oncology-clinical-trial-collaboration-300656793.html

NKTR is furnishing free drug for the phase-1/2 clinical trial, but no cash.
👍️0
DewDiligence DewDiligence 7 년 전
SNDX ENCORE-601 update…

PR:
https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-300650233.html

CC slides:
http://ir.syndax.com/static-files/7c0c8627-0b81-43d6-9210-6cb02684db5f
👍️0
tika1 tika1 7 년 전
After failure of two high profile IO combination, I think SNDX will go nowhere for its own IO combo.

All eyes on Etinostat + exemestane only. Still chance of double, if that turns out good.
👍️0
DewDiligence DewDiligence 7 년 전
Transcript of SNDX 1Q18 CC:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-235620976.html
👍️0
DewDiligence DewDiligence 7 년 전
SNDX new investor slide set:

http://ir.syndax.com/static-files/da19e99b-2bd2-4456-91fe-0e67b97fc0d0
👍️0
DewDiligence DewDiligence 7 년 전
The 1Q18 10-Q has been filed:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-10q_20180331.htm
👍️0
DewDiligence DewDiligence 7 년 전
SNDX 1Q18 results—cash=$113M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-clinical-and-business-update-300644832.html
👍️0
DewDiligence DewDiligence 7 년 전
SNDX ASCO lineup:

https://finance.yahoo.com/news/syndax-pharmaceuticals-announces-presentations-2018-200500073.html
👍️0
DewDiligence DewDiligence 7 년 전
Yes—please see my reply in #msg-140012720.
👍️0
tika1 tika1 7 년 전
Dew,
Is there any hope for success of this trial after high profile INCY failure? What is your take on SNDX current weakness?


Oral Presentations:

Title: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial
Presenter: Anthony W. Tolcher, M.D.
Category: Clinical Trials
Session: Biomarkers in Immuno-oncology
Abstract Number: CT179
Location: N Hall C - McCormick Place North (Level 1)
Date and Time: Tuesday April 17, 2018; 3:50 PM - 4:05 PM C.T.
👍️0
DewDiligence DewDiligence 7 년 전
SNDX presentation lineup at AACR:

https://finance.yahoo.com/news/syndax-present-2018-american-association-110000742.html
👍️0

최근 히스토리

NASDAQ
SNDX
Syndax Pharmaceuticals
BIT
UB26GR
UniCredit Bank
USOTC
BOPO
BioPower Operations (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지